How Disease Cardiomyocytes Impact Drug Discovery – ISSCR 2016

Please stop by our posters at ISSCR 2016 to visit our scientists and learn more about exciting advances using our cardiomyocyte  models:

Wednesday June 22, 6:30 – 7:30 pm  A Unique Combination of SMarTR Bioinformatics and Cardiomyocyte Screening Technology Allows for Development of Novel Cardio-protective Drugs (abstract# 2684, poster #W1083)

Wednesday June 22, 7:30 – 8:30 pm Phenotype Variability of iPSC-derived Cardiomyocytes from Patients with Distinct Mutations for Familial Hypertrophic Cardiomyopathy can Inform Drug Discovery (abstract# 2785, poster # W1072)

Thursday June 23, 6:00 – 7:00 pm  Use of Engineered Cardiac Tissue Constructs (ECTs) as a Model for Studying Human Cardiac Diseases (abstract# 2693, poster# T3047 )

 

Interested in developing cardioprotective drugs?

Join Nirupama Pike at the Precision Medicine & Bioprocessing Conference June 8th in the San Francisco Bay Area where she will be speaking about a unique combination of SMarTR bioinformatics and cardiomyocyte screening that allows for the development of novel cardioprotective drugs.

The conference will feature selected keynote presentations by precision medicine-focused biotechnology companies developing novel therapies for heart failure, cancer and resourceful technology platforms addressing a broad range of diseases.

Stem Cell Theranostics Receives a Phase 1 SBIR Grant from the National Science Foundation to Develop a Novel Drug Discovery Platform for Genetic Heart Disease

Redwood City, CA, December 17, 2015 – Stem Cell Theranostics (SCT) announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Science Foundation (NSF). The grant is focused on developing a novel in vitro assay platform using patient-derived cardiomyocytes to screen for drugs to treat hypertrophic cardiomyopathy.

 

Familial Hypertrophic cardiomyopathy (HCM) affects 1 in 200 people in the world. It is the most common of the inherited cardiovascular diseases. Patients with HCM exhibit abnormal thickening of the left ventricular myocardium and are at heightened risk for clinical complications such as arrhythmia, progressive heart failure and sudden cardiac death. Attempts to develop novel therapies specific to HCM have been hampered by a lack of relevant, pre-clinical disease models for use in drug screening. Stem Cell Theranostics in partnership with the Stanford Cardiovascular Institute, have developed a comprehensive BioBank of human induced pluripotent stem cells (iPSC) derived cardiomyocytes from patients with HCM and other inherited heart conditions. These models form the basis of our translational discovery platform for identifying novel therapies for rare genetic heart diseases.

 

“We are delighted to have the backing of the National Science Foundation with this highly competitive award,” said Chris Armstrong PhD, President and CEO. “HCM and other genetic heart diseases represent a significant unmet medical need. Our work in developing novel human-derived stem cell models for HCM promises to enable the discovery of novel therapies that target the underlying genetic defects”.

 

About Stem Cell Theranostics Inc

Stem Cell Theranostics is a discovery stage biotechnology company focused on developing therapies for genetic and drug-induced heart disease. Through our exclusive partnership with Stanford University Cardiovascular Institute, we have developed a powerful discovery platform that focuses on the generation and use of stem cell-derived, patient-specific cardiac models in drug screening and therapeutic development.

 

Media Inquires:

 

Rachel Bolger

Director of Marketing

Stem Cell Theranostics

608.441.8375

www.sctheranostics.com

Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies

Redwood City, CA and Palo Alto, CA, December 16, 2015 – Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent cardiotoxicity associated with various oncology drugs. By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs.

Cancer survivors have an 8-fold higher risk of death from cardiac-related events than the general population and a 15-fold increased risk of developing heart failure. The underlying cause has been attributed to the effects of cardiotoxic cancer therapies such as anthracyclines, protein kinase inhibitors and antibody therapies.

The first collaborative program is focused on discovering cardioprotective drugs to prevent anthracycline-induced cardiotoxicity. There is currently only one FDA-approved agent, Dexrazoxane, but this has limited indication approval and has not been widely used due to concerns that it may interfere with the anti-tumor activity of anthracyclines. Novel cardioprotectants with improved efficacy and safety profiles that could be used across multiple indications would offer significant clinical benefit.

“Combining a computational biomedicine approach with advanced iPSC-derived preclinical models promises to dramatically accelerate the discovery of novel therapies,” said Chris Armstrong, CEO of Stem Cell Theranostics. “In less than 6 months, our collaboration with CapellaBio has led to the discovery and validation of several promising cardioprotectant drug leads with best-in-class properties.”

“We are very fortunate to have an excellent partner like SCT. Together, we have identified drug candidates at an unprecedented speed for an unmet medical need in cancer treatment,” said Pek Lum, founder and CEO of CapellaBio.   “These promising drug candidates demonstrate strong biological profiles and signatures. Our work in validating these candidates in human-derived stem cells models confirms that these compounds are extremely promising leads.”

 “Cardiovascular disease caused by cancer therapies is a significant and growing clinical problem,” said Dr. Robert C. Robbins, President and CEO, Texas Medical Center.  “Cardio-Oncology programs like this, that focus on developing therapies to prevent heart damage caused by chemotherapy, are essential to not only improve the quality of life of cancer survivors, but to also reduce the economic burden on the healthcare system.”

About Stem Cell Theranostics Inc

Stem Cell Theranostics is a discovery stage biotechnology company focused on developing therapies for genetic and drug-induced heart disease. Through our exclusive partnership with Stanford University Cardiovascular Institute, we have developed a powerful discovery platform that focuses on the generation and use of stem cell-derived, patient-specific cardiac models in drug screening and therapeutic development.

About CapellaBio

CapellaBio is a Silicon Valley based computational pharmaceutical company. CapellaBio applies novel data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. At the heart of CapellaBio’s analysis pipeline is the SMarTR engine, a proprietary, highly automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds that will be effective for specific patient sub-populations.

Media Inquires:

Rachel Bolger

Director of Marketing

Stem Cell Theranostics

608.441.8375

www.sctheranostics.com

 

Viwat Visuthikraisee

Chief Operating Officer

CapellaBio

info@capellabio.com

www.capellabio.com

 

Stem Cell Theranostics and Thermo Fisher Scientific Announce Collaboration to Advance Cardiomyopathy Disease Modeling Workflows

Madison, WI and Redwood City, CA, July 1, 2015 – Stem Cell Theranostics (SCT) announced today that they have successfully completed a research collaboration with Thermo Fisher Scientific focused on advancing the development of cardiac disease models derived from induced pluripotent stem cells using Thermo Fisher Scientific’s suite of work flow reagents and SCT’s patient biobank and proprietary disease modeling methods.

Through this collaboration, scientists at Stem Cell Theranostics used Thermo Fisher Scientific workflow reagents to develop stem cell-derived cardiomyocytes from patients with inherited hypertrophic cardiomyopathy (HCM). The resulting cardiomyocytes displayed many of the features of disease, including irregular heart beat and enlarged cell size, making them a promising model for drug discovery and therapeutic development.

Cardiovascular disease is the number one cause of death in the world. The cost, both in lives and resources, is enormous. Despite the cost to society the development of specific, effective cardiovascular drugs is lagging and prevalent diseases like HCM, a disease that affects 1 in 500 people, are managed by treating symptoms not the underlying disease. Current models used to screen the effectiveness of drugs prior to clinical testing in humans do not accurately represent the characteristics of the human heart and are not predictive of clinical trial success. Developing drug-screening models that more accurately represent disease will enable the development of new and more effective drugs.

“The ability to reproducibly generate stem cell-derived cardiac disease models requires both standardized workflows and highly reproducible technologies and reagents,” said Chris Armstrong, CEO of Stem Cell Theranostics. “Our success with Thermo Fisher Scientific’s workflow reagents, in particular their reagents for the generation of cardiomyocytes from pluripotent stem cells, has enabled us to develop a broad panel of patient-derived cardiomyocyte models to study inherited heart disease.”

About Stem Cell Theranostics Inc

Stem Cell Theranostics is a California-based biotechnology company that is accelerating the discovery and development of novel medicines for heart disease using patient-derived cardiac disease models. Through our exclusive partnership with Stanford University Cardiovascular Institute, we have developed a powerful discovery platform that focuses on the generation and use of stem cell-derived, patient-specific cardiac disease models in drug screening and therapeutic development. Discover more at www.sctheranostics.com.

Media Inquires:

Rachel Bolger
Director of Marketing
Stem Cell Theranostics
608.441.8375
http://www.sctheranostics.com

Stem Cell Theranostics and GE Healthcare Announce Sublicense for Stem Cell Patents

Redwood City, CA, July 1, 2015 –  Stem Cell Theranostics, Inc., the Cardiac Disease Modeling Specialists announced today that it has signed a sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property relating to the use of human induced pluripotent stem cells, enabling Stem Cell Theranostics to develop and manufacture cardiomyocytes derived from stem cells for use in drug discovery and toxicity. Financial terms were not disclosed.

This follows a March 2015 announcement in which Stem Cell Theranostics, Inc. and iPS Academia Japan Inc. signed a non-exclusive agreement granting Stem Cell Theranostics worldwide access to the induced Pluripotent Stem (iPS) cells patent portfolio.

“These agreements provide Stem Cell Theranostics with a powerful technology portfolio to develop our patient-derived cardiac disease modeling platform,” said Chris Armstrong, PhD, President and CEO, Stem Cell Theranostics, Inc. “The ability to provide researchers with freedom to operate is critical to advancing therapeutic discovery”

Sian Godwin, Head of Life Sciences Licensing, GE Healthcare said: “Our extensive IP portfolio of novel technologies with drug discovery and development applications means GE Healthcare can actively support progress and growth in the industry by doing deals with forward-thinking companies such as this one with Stem Cell Theranostics.”

The licensed technologies will be used by Stem Cell Theranostics to generate a comprehensive biobank of iPSC lines derived from controls and patients suffering from genetic and acquired heart disease.  These IPSCs will be used to develop cellular disease models for use in drug discovery and development.

About Stem Cell Theranostics Inc

Stem Cell Theranostics is a California-based biotechnology company that is accelerating the discovery and development of novel medicines for heart disease using patient-derived cardiac disease models. Through our exclusive partnership with Stanford University Cardiovascular Institute, we have developed a powerful discovery platform that focuses on the generation and use of stem cell-derived, patient-specific cardiac disease models in drug screening and therapeutic development. Discover more at www.sctheranostics.com.

Media Inquires:

Rachel Bolger
Director of Marketing
Stem Cell Theranostics
608.441.8375
http://www.sctheranostics.com

Stem Cell Theranostics and iPS Academia Japan announce iPSC patent portfolio agreement

California, USA. March 24th –  Stem Cell Theranostics, Inc., the Cardiac Disease Modeling Specialists, and iPS Academia Japan Inc. (Kyoto, Japan) announced today that they have signed a non-exclusive agreement granting Stem Cell Theranostics worldwide access to the induced Pluripotent Stem (iPS) cells patent portfolio developed by Professor Shinya Yamanaka, MD, PhD, “Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan.”

[Read more…]